Risk factors

Ocugen faces high risk as a clinical-stage biotechnology company with no commercialized products and $58.5 million in cash as of December 31, 2024. The company is heavily dependent on the clinical success and regulatory approval of unproven platforms like modifier gene therapy and OCU200 biologics. Financial constraints require substantial additional funding, creating risks of dilution, clinical delays, or operational curtailment.

Okta faces risks from intense competition, evolving privacy regulations, and security or bug issues that could cause service outages.

Office space demand has dropped due to remote work trends and government downsizing initiatives. Leases covering 13.5 percent of annualized base rent expire in 2025. Outstanding consolidated indebtedness totals 492.0 million dollars alongside joint venture liquidity issues.

The risk section is dominated by risks related to BDC regulatory status, valuation uncertainty of illiquid portfolio investments, and capital raising constraints.

Ring Energy's risk profile is dominated by commodity price volatility, debt levels, and operational execution in horizontal drilling.

Riley Exploration Permian faces significant risks related to seismic activity and wastewater regulations in the Permian Basin. Capital intensity, debt covenants, and commodity price volatility heavily constrain operations and financing. Asset concentration in specific fields and reliance on third-party operators create operational vulnerabilities.

Solaris Energy Infrastructure faces substantial risks from oil and gas price volatility and oilfield capital spending cycles. Entry into distributed power and the MER acquisition bring new integration, regulation, and supplier concentration risks. The Power Solutions segment is significantly dependent on a single data center client.

Sensus Healthcare relies heavily on sales of its SRT-100 product line for non-melanoma skin cancer treatments. Operations depend on a single preferred supplier for x-ray tubes and third-party reimbursement coverage. Regulatory compliance under healthcare laws and FDA reporting is critical to ongoing business success.

Stem faces execution risks following its October 2024 strategy shift toward software services amid significant past net losses.

Silvaco Group faces heavy industry competition and relies heavily on semiconductor end markets.

Pool sales depend heavily on consumer discretionary spending, homeownership rates, and favorable weather conditions. Global sourcing of PVC and other raw materials creates supply chain vulnerabilities. Substantial variable-rate debt and significant intangible assets create financial sensitivity.

Clinical stage biopharmaceutical company with no revenue, developing TARA-002 and IV Choline Chloride. Heavily dependent on third-party manufacturers, Chugai agreements, and external clinical trial enrollment. Subject to extensive regulatory requirements and ongoing financing needs.